A study conducted by Loretelli et al. shows that targeting the IL-8 and C-X-C chemokine receptor types 1 and 2 (CXCR1/2) axis may reduce the burden of diabetic kidney disease [30]. This evidence concerns the gene CXCL8 and diabetic kidney disease.